Background An open-label study indicated that selective depletion of B cells with the use of
rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To …

… The n/m represents patients with ≥1 occurrence of the abnormality (n)/patients with ≥1
postbaseline value (m). The apremilast-exposure period (wk 0-52) included all patients who …

Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators.
Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared …

The neuropeptide substance P has been implicated in the pathogenesis of inflammation
and pain in arthritis. In this double-blind randomized study, 70 patients with osteoarthritis (OA) …

We have identified and sequenced a cDNA encoding human neutrophil collagenase from a
lambda gt11 cDNA library constructed from mRNA extracted from the peripheral leukocytes …

Objective To evaluate apremilast treatment in patients with active psoriatic arthritis,
including current skin involvement, despite prior therapy with conventional disease-modifying …

… M. Vogel et al. … Randall M. Stevens, MD, …

Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

Phosphodiesterase 4 (PDE4) is a key enzyme in the degradation of cyclic adenosine
monophosphate and is centrally involved in the cytokine production of inflammatory cells, …

… Address correspondence to Randall M. Stevens, MD, Centrexion Therapeutics Corp.,
200 State Street, 6th Floor, Boston, MA 02109. E-mail: rstevens@centrexion.com. …